Efficacy and safety of bevacizumab plus chemotherapy in treatment of patients with metastatic colorectal cancer
10.3760/cma.j.issn.1006-9801.2014.11.006
- VernacularTitle:贝伐珠单抗联合化疗治疗转移性结直肠癌的近期效果及安全性
- Author:
Ninggang ZHANG
;
Yusheng WANG
;
Chenyan ZHANG
;
Xiuxiu LI
;
Xiangyu CHEN
;
Lu WEN
- Publication Type:Journal Article
- Keywords:
Colonic neoplasms;
Rectal neoplasms;
Molecular targeted therapy;
Bevacizumab;
Antineoplastic combined chemotherapy protocols
- From:
Cancer Research and Clinic
2014;26(11):741-743,748
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and safety of Bevacizumab (Bev) combined with chemotherapy protocols in the patients with metastatic colorectal cancer (mCRC).Methods 43 patients with mCRC were treated with Bev combined with various of chemotherapy protocols.The efficacy was assessed based on Response Evaluation Criterion for Solid Tumors (RECIST),and the adverse events were evaluated according to National Cancer Institute-Common Toxicity Criterion for Adverse Events (NCI-CTCAE) 3.0.Results The data of 43 patients (16 males and 27 females) were analyzed.17 patients achieved partial remission (PR),19 patients stable disease (SD) and 7 patients progressive disease (PD).The median progression-free survival (PFS) time was 10.3 months.The major of 3-4 adverse events included leucocytopenia,neutropenic febrile,and nausea/vomiting.Bey-associated adverse events were proteinuria,hypertension,rhinorrhagia,hemorrhagic hemorrhoid,menstrual blood increased,gastrointestinal perforation and venous thrombosis.Conclusions Bey combined with various chemotherapy protocols is more effective for patients with mCRC.Most patients can tolerate the side effects of the combined treatment.The long-term effects of the combined treatment need to be followed up.
